Sánchez Gómez E, Pérez Pérez M, Huesa Martínez J I, Campoy Moreno J R
Servicio de Urología, Hospital Universitario Virgen del Rocio, Sevilla, España.
Arch Esp Urol. 1995 May;48(4):365-7.
This study describes our experience in the treatment of disseminated prostatic cancer with stramustine phosphate.
We reviewed our series of 41 patients with disseminated prostatic cancer; of these, 6 were treated with stramustine phosphate. Patient age, clinical features, tumor stage and diagnostic methods utilized were analyzed. All patients received 600 mg/day oral stramustine in two doses.
All 6 patients treated with stramustine phosphate showed clinical improvement, the levels of tumor markers returned to normal and bone metastasis disappeared. Moreover, no side effects were observed.
Further research is necessary on the effective use of stramustine phosphate and at the appropriate time in order to obtain the best results as there is no other alternative except radical surgery and at an early stage.
本研究描述了我们使用磷酸雌莫司汀治疗播散性前列腺癌的经验。
我们回顾了41例播散性前列腺癌患者的病例系列;其中6例接受了磷酸雌莫司汀治疗。分析了患者年龄、临床特征、肿瘤分期以及所采用的诊断方法。所有患者均接受每日600毫克口服磷酸雌莫司汀,分两次给药。
所有6例接受磷酸雌莫司汀治疗的患者均显示临床症状改善,肿瘤标志物水平恢复正常,骨转移消失。此外,未观察到副作用。
由于除了早期根治性手术外没有其他选择,因此有必要进一步研究磷酸雌莫司汀的有效使用方法及合适时机,以获得最佳效果。